SCPH
Income statement / Annual
Last year (2023), scPharmaceuticals Inc.'s total revenue was $13.59 M,
and the percentage change from the previous year is not available.
In 2023, scPharmaceuticals Inc.'s net income was -$54.81 M.
See scPharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$13.59 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$3.81 M |
$468,000.00 |
$438,000.00 |
$399,000.00 |
$364,000.00 |
$332,000.00 |
$167,000.00 |
$5,000.00 |
$4,000.00 |
| Gross Profit |
$9.78 M |
-$468,000.00 |
-$438,000.00 |
-$399,000.00 |
-$364,000.00 |
-$332,000.00 |
-$167,000.00 |
-$5,000.00 |
-$4,000.00 |
| Gross Profit Ratio |
0.72 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$11.81 M
|
$15.53 M
|
$16.04 M
|
$18.15 M
|
$24.63 M
|
$15.95 M
|
$14.33 M
|
$11.86 M
|
$8.27 M
|
| General & Administrative
Expenses |
$53.37 M
|
$20.62 M
|
$9.78 M
|
$11.78 M
|
$8.27 M
|
$13.72 M
|
$9.11 M
|
$6.05 M
|
$2.58 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$53.37 M
|
$20.62 M
|
$9.78 M
|
$11.78 M
|
$8.27 M
|
$13.72 M
|
$9.11 M
|
$6.05 M
|
$2.58 M
|
| Other Expenses |
$0.00 |
$1.42 M |
$315,000.00 |
-$4,000.00 |
$16,000.00 |
-$56,000.00 |
$75,000.00 |
$38,000.00 |
-$68,000.00 |
| Operating Expenses |
$65.18 M |
$36.16 M |
$25.82 M |
$29.93 M |
$32.91 M |
$29.67 M |
$23.44 M |
$17.91 M |
$10.84 M |
| Cost And Expenses |
$68.99 M |
$36.16 M |
$25.82 M |
$29.93 M |
$32.91 M |
$29.67 M |
$23.44 M |
$17.91 M |
$10.84 M |
| Interest Income |
$5.10 M |
$1.20 M |
$49,000.00 |
$315,000.00 |
$1.66 M |
$1.71 M |
$341,000.00 |
$7,000.00 |
$0.00 |
| Interest Expense |
$8.12 M |
$3.30 M |
$2.58 M |
$2.59 M |
$1.77 M |
$1.43 M |
$797,000.00 |
$6.51 M |
$0.00 |
| Depreciation &
Amortization |
$626,000.00
|
$468,000.00
|
$438,000.00
|
$399,000.00
|
$364,000.00
|
$332,000.00
|
$167,000.00
|
$5,000.00
|
$4,000.00
|
| EBITDA |
-$46.06 M
|
-$33.07 M
|
-$25.02 M
|
-$29.22 M
|
-$30.87 M
|
-$27.68 M
|
-$25.15 M
|
-$17.86 M
|
-$10.84 M
|
| EBITDA Ratio |
-3.39 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-4.08
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$586,000.00
|
-$681,000.00
|
-$2.21 M
|
-$2.28 M
|
-$91,000.00
|
$224,000.00
|
-$381,000.00
|
-$6.47 M
|
$326,000.00
|
| Income Before Tax |
-$54.81 M |
-$36.84 M |
-$28.03 M |
-$32.21 M |
-$33.00 M |
-$29.44 M |
-$23.82 M |
-$24.38 M |
-$10.52 M |
| Income Before Tax Ratio
|
-4.03
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$681,000.00 |
$2.45 M |
$2.18 M |
$1.42 M |
-$224,000.00 |
$381,000.00 |
$6.47 M |
-$326,000.00 |
| Net Income |
-$54.81 M |
-$37.52 M |
-$30.49 M |
-$34.39 M |
-$34.42 M |
-$29.44 M |
-$23.82 M |
-$24.38 M |
-$10.52 M |
| Net Income Ratio |
-4.03 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.42 |
-1.32 |
-1.11 |
-1.4 |
-1.85 |
-1.59 |
-8.04 |
-2.18 |
-0.94 |
| EPS Diluted |
-1.42 |
-1.32 |
-1.11 |
-1.4 |
-1.85 |
-1.59 |
-8.04 |
-2.18 |
-0.94 |
| Weighted Average Shares
Out |
$38.51 M
|
$28.36 M
|
$27.35 M
|
$24.57 M
|
$18.60 M
|
$18.56 M
|
$2.96 M
|
$11.20 M
|
$11.20 M
|
| Weighted Average Shares
Out Diluted |
$38.51 M
|
$28.36 M
|
$27.35 M
|
$24.57 M
|
$18.60 M
|
$18.56 M
|
$2.96 M
|
$11.20 M
|
$11.20 M
|
| Link |
|
|
|
|
|
|
|
|
|
